NCT00264238View on ClinicalTrials.gov

Memantine Augmentation in Obsessive-Compulsive Disorder

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Obsessive-Compulsive Disorder
Interventions
DRUG

Memantine

pharmacological dosing of memantine as adjunctive therapy for treatment-resistant obsessive-compulsive disorder

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT00264238 - Memantine Augmentation in Obsessive-Compulsive Disorder | Biotech Hunter | Biotech Hunter